Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30
$1.33−0.07 (-5.34%)
Close on Nov 17, 2026Market cap $124.65MP/E –Yield –
Innate Pharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
For fiscal 2025 it was -€52.76M. The highest annual figure on record is €34.92M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€52.76M | – |
| FY2024 | Dec 31, 2024 | -€6.90M | – |
| FY2023 | Dec 31, 2023 | -€32.56M | – |
| FY2022 | Dec 31, 2022 | -€19.16M | – |
| FY2021 | Dec 31, 2021 | -€58.46M | – |
| FY2020 | Dec 31, 2020 | -€51.77M | -248.2% |
| FY2019 | Dec 31, 2019 | €34.92M | – |
| FY2018 | Dec 31, 2018 | -€32.53M | – |
| FY2017 | Dec 31, 2017 | -€48.06M | – |
See a number that looks wrong?